Objective To analyze the characteristics of retinal pigment epithelium (RPE) tears following the injection of intravitreal anti-vascular endothelial growth factor (VEGF) for the treatment of age-related macular degeneration (AMD). Methods A comprehensive literature review of RPE tears following anti-VEGF therapy for AMD was conducted using the PubMed and CBM disc databases, and the features of RPE tears were summarized. Results A total of 35 studies from the literature were included. The average age of patients who developed RPE tears was 78.6 years (range 59-96 years), and the average injection times before tears developed was 1.6 (range 1-4). The mean duration time between the first injection and diagnosis was 34.8 d (range 1 d-4 months). Despite the development of RPE tears, anti-VEGF therapy can still inhibit choroidal neovascularization. Compared to visual acuity before injection, most patients had better or stable visual acuity (81.4%) even with the development of RPE tears. With an average follow-up of 94.9 days, most patients had stable or better visual acuity (83.3%). Conclusion Although anti-VEGF therapy for AMD may induce RPE tearing, this complication does not predominantly affect vision. Large-size pigment epithelial detachment (PED) is a risk factor for RPE tears, especially with large or high vascular PED.